TLR agonists as modulators of the innate immune response and their potential as agents against infectious disease

Frontiers in Immunology

Volumn 5, Issue MAR, 2014, Pages

  Mifsud, Edin J ^a   Tan, Amabel C L ^a   Jackson, David C ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cytokines and inflammation; Immunomodulation; Innate immunity; TLR agonists; Toll like receptors

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PATTERN RECOGNITION RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC RESISTANCE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; DISEASE CONTROL; HEPATITIS C; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; INNATE IMMUNITY; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; SIGNAL TRANSDUCTION; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION;

EID: 84897951148     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00079     Document Type: Review

References (115)

1. Poland GA. Pharmacology, vaccinomics, and the second golden age of vaccinology. Clin Pharmacol Ther (2007) 82:623-6. doi: 10.1038/sj.clpt.6100379
2. Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ (2008) 86:81-160. doi:10.2471/BLT.07.040089
3. Levine MM, Robins-Browne R. Vaccines, global health and social equity. Immunol Cell Biol (2009) 87:274-8. doi:10.1038/icb.2009.15
4. Neu HC. The crisis in antibiotic resistance. Science (1992) 257:1064-73. doi:10.1126/science.257.5073.1064
5. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet (2005) 366:1165-74. doi:10.1016/S0140-6736(05)67339-4
6. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, Kleppinger A, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol (2006) 176:6333-9.
7. Wissinger E, Goulding J, Hussell T. Immune homeostasis in the respiratory tract and its impact on heterologous infection. Semin Immunol (2009) 21:147-55. doi:10.1016/j.smim.2009.01.005
8. Anders E, Hartley C, Jackson D. Bovine and mouse serum beta inhibitors of influenza A viruses are mannose-binding lectins. Proc Natl Acad Sci U S A (1990) 87:4485-9. doi:10.1073/pnas.87.12.4485
9. Benne CA, Kraaijeveld CA, van Strijp JA, Brouwer E, Harmsen M, Verhoef J, et al. Interactions of surfactant protein a with influenza a viruses: binding and neutralization. J Infect Dis (1995) 171:335-41. doi:10.1093/infdis/171.2.335
10. Reading PC, Morey LS, Crouch EC, Anders EM. Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice. J Virol (1997) 71:8204-12.
11. Aujla SJ, Chan YR, Mingquan Z, Mingjian F, Askew DJ, Pociask DA, et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med (2008) 14:275-81. doi:10.1038/nm1710
12. Evans SE, Xu Y, Tuvim MJ, Dickey BF. Inducible innate resistance of lung epithelium to infection. Annu Rev Physiol (2010) 72:413-35. doi:10.1146/annurev-physiol-021909-135909
13. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 5:987-95. doi:10.1038/ni1112
14. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol (2007) 7:179-90. doi:10.1038/nri2038
15. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 11:373-84. doi:10.1038/ni.1863
16. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol (2005) 17:1-14. doi:10.1093/intimm/dxh186
17. O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors-redefining innate immunity. Nat Rev Immunol (2013) 13:453-60. doi:10.1038/nri3446
18. Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL. Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol (2008) 8:142-52. doi:10.1038/nri2236
19. Thepen T, Van Rooijen N, Kraal G. Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J Exp Med (1989) 170:499-509. doi:10.1084/jem.170.2.499
20. Fernandez S, Jose P, Avdiushko MG, Kaplan AM, Cohen DA. Inhibition of IL-10 receptor function in alveolar macrophages by toll-like receptor agonists. J Immunol (2004) 172:2613-20.
21. Hashimoto G, Wright PF, Karzon DT. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis (1983) 148:785-94. doi:10.1093/infdis/148.5.785
22. Pierangeli SS, Sonnenfeld G. Treatment of murine macrophages with murine interferon-gamma and tumour necrosis factor-alpha enhances uptake and intracellular killing of Pseudomonas aeruginosa. Clin Exp Immunol (1993) 93:165-71. doi:10.1111/j.1365-2249.1993.tb07960.x
23. Stein-Streilein J, Bennett M, Mann D, Kumar V. Natural killer cells in mouse lung: surface phenotype, target preference, and response to local influenza virus infection. J Immunol (1983) 131:2699-704.
24. Grégoria C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, et al. The trafficking of natural killer cells. Immunol Rev (2007) 220:169-82. doi:10.1111/j.1600-065X.2007.00563.x
25. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature (1998) 392:245-52. doi:10.1038/32588
26. Reppe K, Tschernig T, Luhrmann A, Van Laak V, Grote K, Zemlin MV, et al. Immunostimulation with macrophage-activating lipopeptide-2 increased survival in murine pneumonia. Am J Respir Cell Mol Biol (2009) 40:474-81. doi:10.1165/rcmb.2008-0071OC
27. Tuvim MJ, Evans SE, Clement CG, Dickey BF, Gilbert BE. Augmented lung inflammation protects against influenza A pneumonia. PLoS One (2009) 4:e4176. doi:10.1371/journal.pone.0004176
28. Baaten BJG, Clarke B, Strong P, Hou S. Nasal mucosal administration of chitin microparticles boosts innate immunity against influenza A virus in the local pulmonary tissue. Vaccine (2010) 28:4130-7. doi:10.1016/j.vaccine.2010.04.026
29. Evans SE, Tuvim MJ, Fox CJ, Sachdev N, Gibiansky L, Dickey BF. Inhaled innate immune ligands to prevent pneumonia. Br J Pharmacol (2011) 163:195-206. doi:10.1111/j.1476-5381.2011.01237.x
30. Tan ACL, Mifsud EJ, Zeng W, Edenborough K, Mcvernon J, Brown LE, et al. Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice. Mol Pharm (2012) 9:2710-8. doi:10.1021/mp300257x
31. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med (2007) 13:552-9. doi:10.1038/nm1589
32. Gerold G, Zychlinsky A, De Diego JL. What is the role of Toll-like receptors in bacterial infections? Semin Immunol (2007) 19:41-7. doi:10.1016/j.smim.2006.12.003
33. Carty M, Bowie AG. Recent insights into the role of Toll-like receptors in viral infection. Clin Exp Immunol (2010) 161:397-406. doi:10.1111/j.1365-2249.2010.04196.x
34. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol (2000) 1:398-401. doi:10.1038/80833
35. Takeuchi O, Hoshino K, Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol (2000) 165:5392-6.
36. Archer KA, Roy CR. MyD88-dependent responses involving toll-like receptor 2 are important for protection and clearance of Legionella pneumophila in a mouse model of Legionnaires' disease. Infect Immun (2006) 74:3325-33. doi:10.1128/iai.02049-05
37. Murawski MR, Bowen GN, Cerny AM, Anderson LJ, Haynes LM, Tripp RA, et al. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol (2009) 83:1492-500. doi:10.1128/jvi.00671-08
38. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med (2005) 202:1715-24. doi:10.1084/jem.20051782
39. Schenk M, Belisle JT, Modlin RL. TLR2 looks at lipoproteins. Immunity (2009) 31:847-9. doi:10.1016/j.immuni.2009.11.008
40. Muhlradt PF, Kiess M, Meyer H, Sussmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from mycoplasma fermentans acting at picomolar concentration. J Exp Med (1997) 185:1951-8. doi:10.1084/jem.185.11.1951
41. Kaufmann A, Muhlradt PF, Gemsa D, Sprenger H. Induction of cytokines and chemokines in human monocytes by mycoplasma fermentans-derived lipoprotein MALP-2. Infect Immun (1999) 67:6303-8.
42. Luhrmann A, Deiters U, Skokowa J, Hanke M, Gessner JE, Muhlradt PF, et al. In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of mycoplasma fermentans after pulmonary application. Infect Immun (2002) 70:3785-92. doi:10.1128/iai.70.7.3785-3792.2002
43. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol (2002) 169:4905-12.
44. Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, Cheers C, et al. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A (2004) 101:15440-5. doi:10.1073/pnas.0406740101
45. Brown LE, Jackson DC. Lipid-based self-adjuvanting vaccines. Curr Drug Deliv (2005) 2:383-93. doi:10.2174/156720105774370258
46. Deliyannis G, Kedzierska K, Lau YF, Zeng W, Turner SJ, Jackson DC, et al. Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol (2006) 36:770-8. doi:10.1002/eji.200535217
47. Chua BY, Zeng W, Jackson DC. Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines. Methods Mol Biol (2008) 494:247-61. doi:10.1007/978-1-59745-419-3_14
48. Tan ACL, Eriksson EMY, Kedzierska K, Deliyannis G, Valkenburg SA, Zeng W, et al. Polyfunctional CD8+ T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope. Antiviral Res (2012) 94:168-78. doi:10.1016/j.antiviral.2012.03.009
49. Tan ACL, Deliyannis G, Bharadwaj M, Brown LE, Zeng W, Jackson DC. The design and proof of concept for a CD8+ T cell-based vaccine inducing cross-subtype protection against influenza A virus. Immunol Cell Biol (2013) 91:96-104. doi:10.1038/icb.2012.54
50. Chua BY, Healy A, Cameron PU, Stock O, Rizkalla M, Zeng W, et al. Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol Cell Biol (2003) 81:67-72. doi:10.1046/j.1440-1711.2003.01133.x
51. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (2001) 413:732. doi:10.1038/35099560
52. Lau Y-F, Tang L-H, Ooi E-E, Subbarao K. Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology (2010) 406:80-7. doi:10.1016/j.virol.2010.07.008
53. Shen EX, Li L, Li LT, Feng LQ, Lu L, Yao ZL, et al. PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA. Cell Mol Immunol (2007) 4:113-20.
54. Stephen EL, Sammons ML, Pannier WL, Baron S, Spertzel RO, Levy HB. Effect of a nuclease-resistant derivative of polyriboinosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (Macaca mulatta). J Infect Dis (1977) 136:122-6. doi:10.1093/infdis/136.1.122
55. Kende M. Prophylactic and therapeutic efficacy of poly(I,C)-LC against Rift Valley fever virus infection in mice. J Biol Response Mod (1985) 4:503-11.
56. Wong JP, Saravolac EG, Sabuda D, Levy HB, Kende M. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza-A virus-infection in mice. Antimicrob Agents Chemother (1995) 39. doi:10.1128/AAC.39.11.2574
57. Wong JP, Christopher ME, Viswanathan S, Karpoff N, Dai X, Das D, et al. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine (2009) 27:3481-3. doi:10.1016/j.vaccine.2009.01.048
58. Wong JP, Yang H, Nagata L, Kende M, Hilton L, Schnell G, et al. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine (1999) 17:1788-95. doi:10.1016/S0264-410X(98)00439-3
59. Antonelli LRV, Gigliotti Rothfuchs A, Gonçalves R, Roffê E, Cheever AW, Bafica A, et al. Intranasal poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest (2010) 120:1674-82. doi:10.1172/jci40817
60. Tian X, Xu F, Lung WY, Meyerson C, Ghaffari AA, Cheng G, et al. Poly I:C enhances susceptibility to secondary pulmonary infections by Gram-positive bacteria. PLoS One (2012) 7:e41879. doi:10.1371/journal.pone.0041879
61. Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, Liu SY, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest (2009) 119:1910-20. doi:10.1172/jci35412
62. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med (2008) 14:558-64. doi:10.1038/nm1765
63. Oliveira EC, Marik PE, Colice G. Influenza pneumonia: a descriptive study. CHEST J (2001) 119:1717-23. doi:10.1378/chest.119.6.1717
64. Schwarzmann SW, Adler JL, Sullivan RJ Jr, Marine WM. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969: experience in a city-county hospital. Arch Intern Med (1971) 127:1037-41. doi:10.1001/archinte.1971.00310180053006
65. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis (2008) 198:962-70. doi:10.1086/591708
66. Lu Y-C, Yeh W-C, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine (2008) 42:145-51. doi:10.1016/j.cyto.2008.01.006
67. Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM, et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol (2002) 10:s32-7. doi:10.1016/S0966-842X(02)02426-5
68. Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine (2000) 18:2416-25. doi:10.1016/S0264-410X(99)00572-1
69. Cluff CW, Baldridge JR, Stover AG, Evans JT, Johnson DA, Lacy MJ, et al. Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun (2005) 73:3044-52. doi:10.1128/iai.73.5.3044-3052.2005
70. Cole LE, Cole BJ, Mann KA, Shirey K, Richard Y, Yang PJ, et al. Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge. J Leukoc Biol (2011) 90:787-97. doi:10.1189/jlb.0111014
71. Classen A, Lloberas J, Celada A. Macrophage activation: classical vs. alternative. In: Reiner NE, editor. Macrophages and Dendritic Cells. New York: Humana Press (2009). p. 29-43.
72. Abdul-Careem MF, Firoz Mian M, Gillgrass AE, Chenoweth MJ, Barra NG, Chan T, et al. FimH, a TLR4 ligand, induces innate antiviral responses in the lung leading to protection against lethal influenza infection in mice. Antiviral Res (2011) 92:346-55. doi:10.1016/j.antiviral.2011.09.004
73. Johnson DA, Gregory Sowell C, Johnson CL, Livesay MT, Keegan DS, Rhodes MJ, et al. Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs). Bioorg Med Chem Lett (1999) 9:2273-8. doi:10.1016/S0960-894X(99)00374-1
74. Stöver AG, Da Silva Correia J, Evans JT, Cluff CW, Elliott MW, Jeffery EW, et al. Structure-activity relationship of synthetic Toll-like receptor 4 agonists. J Biol Chem (2004) 279:4440-9. doi:10.1074/jbc.M310760200
75. Lembo A, Pelletier M, Iyer R, Timko M, Dudda JC, West TE, et al. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J Immunol (2008) 180:7574-81.
76. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature (2001) 410:1099-103. doi:10.1038/35074106
77. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet (2009) 374:1543-56. doi:10.1016/S0140-6736(09)61114-4
78. Munoz N, Van Maele L, Marques JM, Rial A, Sirard J-C, Chabalgoity JA. Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect Immun (2010) 78:4226-33. doi:10.1128/iai.00224-10
79. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A (2004) 101:5598-603. doi:10.1073/pnas.0400937101
80. Schiller M, Metze D, Luger TA, Grabbe S, Gunzer M. Immune response modifiers-mode of action. Exp Dermatol (2006) 15:331-41. doi:10.1111/j.0906-6705.2006.00414.x
81. Miller RL, Imbertson LM, Reiter MJ, Gerster JF. Treatment of primary herpes simplex virus infection in guinea pigs by Imiquimod. Antiviral Res (1999) 44:31-42. doi:10.1016/S0166-3542(99)00052-2
82. Pagano JS, Blaser M, Buendia M-A, Damania B, Khalili K, Raab-Traub N, et al. Infectious agents and cancer: criteria for a causal relation. Semin Cancer Biol (2004) 14:453-71. doi:10.1016/j.semcancer.2004.06.009
83. Mokhtari M, Mesbah A, Rajabi P, Rajabi MA, Chehrei A, Mougouei K. Determination of the relationship between basal cell carcinoma and human papilloma virus, based on immunohistochemistry staining method. Indian J Dermatol (2009) 54:225-8. doi:10.4103/0019-5154.55629
84. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol (2004) 50:722-33. doi:10.1016/j.jaad.2003.10.433
85. Barton JC. Angioedema associated with Imiquimod. J Am Acad Dermatol (2004) 51:477-8. doi:10.1016/j.jaad.2004.01.037
86. Gilliet M, Conrad C, Geiges M. Psoriasis triggered by toll-like receptor 7 agonist Imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol (2004) 140:1490-5. doi:10.1001/archderm.140.12.1490
87. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol (1996) 157:1840-5.
88. Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α. Cell Immunol (1996) 167:72-8. doi:10.1006/cimm.1996.0009
89. Pisetsky DS. Immune activation by bacterial DNA: a new genetic code. Immunity (1996) 5:303-10. doi:10.1016/S1074-7613(00)80256-3
90. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, et al. Cutting edge: CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol (1998) 160:3627-30.
91. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol (1999) 162:2291-8.
92. Kradin RL, Liu H-W, Van Rooijen N, Springer KIM, Zhao L-H, Leary CP. Pulmonary immunity to Listeria is enhanced by elimination of alveolar macrophages. Am J Respir Crit Care Med (1999) 159:1967-74. doi:10.1164/ajrccm.159.6.9810117
93. Harandi AM, Eriksson K, Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol (2003) 77:953-62. doi:10.1128/JVI.77.2.953-962.2003
94. Gill N, Deacon PM, Lichty B, Mossman KL, Ashkar AA. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of toll-like receptor ligands correlates with beta interferon production. J Virol (2006) 80:9943-50. doi:10.1128/jvi.01036-06
95. Herbst MM, Pyles RB. Immunostimulatory CpG treatment for genital HSV-2 infections. J Antimicrob Chemother (2003) 52:887-9. doi:10.1093/jac/dkg481
96. McCluskie MJ, Cartier JLM, Patrick AJ, Sajic D, Weeratna RD, Rosenthal KL, et al. Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and Resiquimod (R-848). Antiviral Res (2006) 69:77-85. doi:10.1016/j.antiviral.2005.10.007
97. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med (2004) 10:187-92. doi:10.1038/nm987
98. Clement CG, Evans SE, Evans CM, Hawke D, Kobayashi R, Reynolds PR, et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med (2008) 177:1322-30. doi:10.1164/rccm.200607-1038OC
99. Evans SE, Scott BL, Clement CG, Larson DT, Kontoyiannis D, Lewis RE, et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol (2010) 42:40-50. doi:10.1165/rcmb.2008-0260OC
100. Duggan JM, You D, Cleaver JO, Larson DT, Garza RJ, Guzman Pruneda FA, et al. Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice. J Immunol (2011) 186:5916-26. doi:10.4049/jimmunol.1002122
101. Li AV, Moon JJ, Abraham W, Suh H, Elkhader J, Seidman MA, et al. Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci Transl Med (2013) 5:204-130. doi:10.1126/scitranslmed.3006516
102. Eddy S, Wim R, Peter V, Tanja R, Jan T, Werner V. Myasthenia gravis-another autoimmune disease associated with hepatitis C virus infection. Dig Dis Sci (1999) 44:186-9. doi:10.1023/a:1026683007277
103. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol (2003) 24:584-8. doi:10.1016/j.it.2003.09.005
104. Christen U, von Herrath MG. Infections and autoimmunity-good or bad? J Immunol (2005) 174:7481-6.
105. Deng G-M, Nilsson I-M, Verdrengh M, Collins LV, Tarkowski A. Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med (1999) 5:702-5. doi:10.1038/9554
106. Boulé MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and-independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med (2004) 199:1631-40. doi:10.1084/jem.20031942
107. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med (2005) 202:321-31. doi:10.1084/jem.20050338
108. Zipris D, Lien E, Nair A, Xie JX, Greiner DL, Mordes JP, et al. TLR9-signaling pathways are involved in Kilham rat virus-induced autoimmune diabetes in the biobreeding diabetes-resistant rat. J Immunol (2007) 178:693-701.
109. Patole PS, Gröne H-J, Segerer S, Ciubar R, Belemezova E, Henger A, et al. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol (2005) 16:1326-38. doi:10.1681/asn.2004100820
110. Gunzer M, Riemann H, Basoglu Y, Hillmer A, Weishaupt C, Balkow S, et al. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood (2005) 106:2424-32. doi:10.1182/blood-2005-01-0342
111. Fidock MD, Souberbielle BE, Laxton C, Rawal J, Delpuech-Adams O, Corey TP, et al. The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther (2011) 89:821-9. doi:10.1038/clpt.2011.60
112. Wong JP, Christopher ME, Salazar AM, Dale RMK, Sun LQ, Wang M. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine (2007) 25:3175-8. doi:10.1016/j.vaccine.2007.01.051
113. Wong JP, Christopher ME, Viswanathan S, Dai X, Salazar AM, Sun LQ, et al. Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses. Curr Pharm Des (2009) 15:1269-74. doi:10.2174/138161209787846775
114. Krieg AM, Love-Homan L, Yi A-K, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol (1998) 161:2428-34.
115. Jiang T, Zhao H, Li X-F, Deng Y-Q, Liu J, Xu L-J, et al. CpG oligodeoxynucleotides protect against the 2009 H1N1 pandemic influenza virus infection in a murine model. Antiviral Res (2011) 89:124-6. doi:10.1016/j.antiviral.2010.11.013